Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenido archivado el 2024-05-27

New Oral Nanomedicines: Transporting Therapeutic Macromolecules across the Intestinal Barrier

Objetivo

Despite the increasing number of macromolecules with potential impact in the treatment of devastating systemic diseases, these therapies have failed to deliver on their expectations because they cannot be administered in the fashion which is most cost efficient and has the highest patient compliance: the oral route. The availability of an oral form of administration could lead to a great improvement of classical therapies and it would also make a high number of new therapies feasible. To make this happen, the final objective of Trans-INT is to design nanocarriers specifically adapted to deal with the gastrointestinal ecosystem and use them for the development of new oral nanomedicines for diseases with high socioeconomic impact (i.e. metabolic diseases, pain medication).

The concept behind TRANS-INT is the rational design of oral nanomedicines based on safety, mechanistic, bioengineering (multifunctional nanocarriers: high payload, drug protection, efficient drug transport, controlled release) and pharmaceutical technology criteria (scalable technology and stability). The project will start with nanocarrier platforms on which the partners have IPR and freedom to operate: nanocapsules, nanoparticles, micelles made of combinations of lipids, polypeptides and polysaccharides, continue with the optimization and redefinition of selected nanocarriers. It is expected to end with (i) at least one oral nanocarrier prototype with a comprehensive GLP-tox package, which could be applied for the delivery of a high number of peptide molecules, (ii) at least one nanomedicine fulfilling target product profile criteria, with a comprehensive preclinical evaluation package, (iii) substantial integrative knowledge on the feasibility and potential of oral nanocarriers and nanopharmaceuticals. TRANS-INT is expected to have a great impact no only from the new therapies/patients perspective but also from the innovation and EU industrial development perspective.

Ámbito científico

Programa(s)

Tema(s)

Convocatoria de propuestas

FP7-NMP-2011-LARGE-5
Consulte otros proyectos de esta convocatoria

Régimen de financiación

CP-IP - Large-scale integrating project

Coordinador

UNIVERSIDAD DE SANTIAGO DE COMPOSTELA
Aportación de la UE
€ 1 665 013,76
Dirección
COLEXIO DE SAN XEROME PRAZA DO OBRADOIRO S/N
15782 Santiago De Compostela
España

Ver en el mapa
Región
Noroeste Galicia A Coruña
Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Martin Cacheiro Martinez (Mr.)
Enlaces
Coste total
Sin datos

Participantes (17)

Compartir esta página

Descargar

Última actualización: 26 Diciembre 2016

Mi folleto

Permalink: https://cordis.europa.eu/project/id/281035/es

European Union, 2024